Related Experiment Video
Updated: Jan 9, 2026
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Indications of Bempedoic Acid
Muhammad Abdullah1, Noman Khalid2, William H Frishman3
1From the Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL.
Insights
Bempedoic acid effectively lowers low-density lipoprotein cholesterol (LDL-C), reducing cardiovascular events, especially in statin-intolerant patients. It offers a valuable option for achieving lipid goals through combination therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is a leading cause of mortality, driven by elevated low-density lipoprotein cholesterol (LDL-C).
- Lowering LDL-C is crucial for reducing atherosclerotic cardiovascular disease events.
- Current guidelines recommend early and sustained LDL-C reduction.
Purpose of the Study:
- To review the evidence and guideline positioning of bempedoic acid in lipid management.
- To highlight bempedoic acid's role in contemporary strategies for LDL-C reduction.
Main Methods:
- Synthesis of current evidence from randomized controlled trials.
- Review of regulatory approvals and guideline recommendations.
- Analysis of bempedoic acid's efficacy and safety profile.
Main Results:
- Bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor, achieves 15-20% LDL-C reduction as monotherapy.
- Combination therapy with ezetimibe can yield up to 40% LDL-C reduction.
- Bempedoic acid demonstrates cardiovascular event reduction in statin-intolerant patients with reduced myotoxicity risk.
Conclusions:
- Bempedoic acid is approved for patients intolerant to statins or inadequately controlled.
- It supports contemporary lipid management emphasizing earlier combination therapy and lower LDL-C thresholds.
- The drug facilitates long-term maintenance of treatment goals for cardiovascular risk reduction.
Abstract:
Cardiovascular disease remains the leading global cause of mortality, with projections indicating a steep rise in prevalence and deaths by 2050. Elevated low-density lipoprotein cholesterol (LDL-C) is a central driver of atherosclerotic cardiovascular disease, and lowering LDL-C consistently reduces major adverse cardiovascular events without an apparent threshold. Recent guidelines underscore both early and durable LDL-C reduction through sequential and combination therapies. Bempedoic acid, an oral first-in-class adenosine triphosphate-citrate lyase inhibitor, offers hepatoselective LDL-C lowering with reduced risk of myotoxicity. Randomized controlled trials demonstrate LDL-C reductions of 15-20% with monotherapy and up to 40% with ezetimibe combination, alongside cardiovascular event reduction in statin-intolerant patients. Regulatory approvals in the United States, European Union, and United Kingdom converge on its role in patients unable to tolerate statins or inadequately controlled on standard therapy. This review synthesizes current evidence and guideline positioning, situating bempedoic acid within contemporary lipid management strategies that emphasize earlier combination therapy, achievement of lower LDL-C thresholds, and long-term maintenance of treatment goals.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:24Diagnosing Acidosis and Alkalosis
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
01:21Drugs for Treatment of Constipation-Predominant IBS